Skip to main content
Clinical Trials/NL-OMON35031
NL-OMON35031
Completed
Not Applicable

Cost-effectiveness of treatment strategies for intermittent claudication - Cost-effectiveness of treatment strategies for intermittent claudication

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intermittent claudication (IC)
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
210
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Rutherford category 1, 2, or 3
  • 2\. Maximum pain\-free walking distance \<350m
  • 3\. ABI \<0\.9 at rest or ABI decreasing by \>0\.15 after the treadmill test;
  • 4\. \>\=1 vascular stenoses of \>50% diameter reduction at the iliac or femoro\-popliteal level.
  • 5\. Informed consent

Exclusion Criteria

  • 1\. Abdominal aortic aneurysm
  • 2\. Life\-incapacitating cardiac disease (NYHA classification III and higher);
  • 3\. Multilevel disease (i.e., same\-side stenoses at both the iliac and femoral levels, requiring multiple revascularization procedures)
  • 4\. Isolated tibial artery disease
  • 5\. Lesions deemed unsuitable for revascularization
  • 6\. Prior treatment for the same lesion (including exercise training)

Outcomes

Primary Outcomes

Not specified

Similar Trials